🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ACGT Research Fellows, and members of the ACGT Scientific Advisory Council, Carl June, MD (Penn), and Michel Sadelain, MD, PhD (Memorial Sloan Kettering Cancer Center), received the Breakthrough Prize for Life Sciences on Saturday! (1/3)

Published today in Blood Journal : "High efficacy of CD19 CAR T-cells in patients with transformed Waldenström macroglobulinemia" from DESCAR-T registry #CART #lymsm Work lead by Eric Durot Lysa Lymphoma, in collaboration with Dana-Farber and Columbia University pubmed.ncbi.nlm.nih.gov/38669635/

Day 2 of the MSK Lymphoma Symposium started with a spectacular session on CNSL #msklymphomacme #mskcme

Amazing news that the FDA approved Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma!  Congrats to Lia Palomba and team!

I’m thrilled that our work reporting the efficacy and unique mechanism of action of romidepsin and duvelisib in T cell lymphoma is out today in Nature Medicine (rdcu.be/dK2g8). A short thread:

Dismantling relapsed/refractory mantle cell lymphoma sciencedirect.com/science/articl…

It was a pleasure discussing some of the clinical implications of our recent Nature Medicine publication on CAR-T related NRM in a Q&A with Memorial Sloan Kettering Cancer Center 👇 #nrm #infections #spm #cartsm #lymsm #mmsm Roni Shouval @DrMiguelPerales mskcc.org/clinical-updat…

Our new study in Blood; we made it to the cover! Congratulations to the team! doi.org/10.1182/blood.… #CART #myeloma #CellTherapy #immunotherapy

Active CNS 🧠 disease is a major challenge for #lymphoma pts planned for CAR T cells. CNS bridging #radiotherapy can rapidly cytoreduce these high risk pts. The Memorial Sloan Kettering Cancer Center initial experience out in Blood Advances Memorial Sloan Kettering Radiation Oncology ashpublications.org/bloodadvances/…

CARs vs bispecifics: the race is on! | Blood | American Society of Hematology ashpublications.org/blood/article/…

25 years Memorial Sloan Kettering Cancer Center! Yea, I’m that old 😉

At the Sunday evening #ASH24 poster session, an important abstract will be presented demonstrating that liso-cel CAR T-cell therapy can cure patients with relapsed DLBCL, with 52% of patients without disease progression at 5 years after CAR-T. #lymsm #tcellrx

Can we develop a new visual language to describe early CAR-T toxicity? 👉 In CAR-TOGRAPHY we graded >32,500 pt days across 4 sites in 902 CAR-T recipients, yielding >125,000 unique toxicity datapoints. 👉 Develop new metrics to describe early toxicity: CTI & tox phenotypes

Happy to share our work just published online in haematologica.org/article/view/1… Haematologica . We dissected the composition and spatial interactions of the TME in GCB, ABC and testicular DLBCLs and found biologically and clinically relevant differences between the subtypes.

The science of pasta cacio e pepe 🇮🇹👨‍🍳 "Finally, we present a scientifically optimized recipe based on our findings, enabling a consistently flawless execution of this classic dish." Applied science at its best, with real-world impact arxiv.org/abs/2501.00536

L.A. Oncologist's Family Is Evacuated, Follows Him to Hospital to Help people.com/doctor-family-…

A phase 1 study led by Jae Park evaluated a novel CAR T cell therapy for people with large B-cell #lymphoma. Of 28 trial participants, the overall response rate was 82% and complete response was 71%. Patients did well on low doses that minimized side effects. #lymsm

New research from Memorial Sloan Kettering Cancer Center takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in nature that demonstrated cells from healthy donors can be stored for future use. bit.ly/40W306e

Please check out our paper published in Nature Medicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical

Nice data, congrats to the authors Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…